COMPASS Pathways appoints Daphne Karydas to its Board of Directors
18 Setembro 2023 - 5:31PM
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology
company dedicated to accelerating patient access to evidence-based
innovation in mental health, today announced the appointment of
Daphne Karydas to its Board of Directors, effective September 18,
2023. Ms. Karydas is President and Chief Financial Officer at Flare
Therapeutics Inc., a privately held biotechnology company targeting
transcription factors to discover precision medicines for cancer
and other diseases.
“Daphne is an ideal match for the COMPASS Pathways Board of
Directors as we progress our phase 3 COMP360 psilocybin program in
treatment-resistant depression and our phase 2 programs in anorexia
nervosa and post-traumatic stress disorder,” said George Goldsmith,
Chairman of the COMPASS Pathways Board of Directors. “Her deep
industry experience, her interdisciplinary approach to implementing
growth strategies for biopharma, and her understanding of investor
priorities will help ensure that the company is on firm financial
and strategic ground as we seek to bring much needed innovation to
patients suffering with serious mental health conditions. We are
delighted to welcome her.”
“I am excited to join the COMPASS board as the company advances
its pioneering COMP360 psilocybin program,” said Ms. Karydas. “Its
recent impressive fundraising round was validation of both the
potential of psychedelic medicine and the rigorous, evidence-based
approach the company is pursuing. I am looking forward to working
with the board and the executive team, and doing my part to advance
COMPASS’s mission.”
Ms. Karydas has over two decades of experience serving in
financial and operations leadership roles with biopharmaceutical
and asset management companies. Prior to joining Flare Therapeutics
in October 2021, Ms. Karydas served as Chief Financial Officer and
Treasurer of Syndax Pharmaceuticals, Inc., and in financial and
strategy roles at Allergan plc, serving as Senior Vice President,
Corporate Financial Planning & Analysis and Strategy at the
time of the company’s acquisition by AbbVie in May 2020. She also
previously held healthcare analyst roles with JPMorgan Asset
Management, The Boston Company Asset Management, and Goldman Sachs
Asset Management, and was a vice president in the healthcare group
of the investment banking division of Goldman, Sachs & Co.
In addition to her experience as an executive, Ms. Karydas also
serves as a board member of Mineralys Therapeutics, a
clinical-stage biopharmaceutical company focused on developing
medicines to target hypertension, chronic kidney disease and other
diseases driven by abnormally elevated aldosterone. She previously
served on the board of LogicBio Therapeutics, a clinical-stage
genomic medicine company that was acquired in 2022 by the rare
disease business group within AstraZeneca, and Elicio Therapeutics,
Inc., a biotechnology company focused on lymph-node targeted
immunotherapies to defeat cancer and infectious diseases.
Ms. Karydas earned BS and MS degrees in chemical engineering
from the Massachusetts Institute of Technology and worked as a
chemical engineer at Merck & Co. following her studies. She
earned her MBA from Harvard Business School.
About COMPASS PathwaysCOMPASS Pathways plc
(Nasdaq: CMPS) is a biotechnology company dedicated to accelerating
patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are suffering with
mental health challenges and who are not helped by current
treatments. We are pioneering the development of a new model of
psilocybin therapy, in which our proprietary formulation of
synthetic psilocybin, COMP360, is administered in conjunction with
psychological support. COMP360 has been designated a Breakthrough
Therapy by the U.S. Food and Drug Administration (FDA) and has
received Innovative Licensing and Access Pathway (ILAP) designation
in the UK for treatment-resistant depression (TRD). We have
commenced a phase 3 clinical program of COMP360 psilocybin therapy
in TRD, the largest randomized, controlled, double-blind psilocybin
therapy clinical program ever conducted. Previously, we completed a
phase 2b study with top line data showing a statistically
significant (p<0.001) and clinically relevant improvement in
depressive symptom severity after three weeks for patients who
received a single 25mg dose of COMP360 psilocybin with
psychological support. We are also conducting phase 2 clinical
studies of COMP360 psilocybin therapy for post-traumatic stress
disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in
London, UK, with offices in New York and San Francisco in the
United States. Our vision is a world of mental
wellbeing. www.compasspathways.com.
Forward-looking statementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. In
some cases, forward-looking statements can be identified by
terminology such as “will”, “may”, “might”, “could”, “would”,
“should”, “expect”, “intend”, “plan”, “objective”, “anticipate”,
“believe”, “contemplate”, “estimate”, “predict”, “potential”,
“continue” and “ongoing,” or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. Forward-looking statements include express or
implied statements relating to, among other things, our
expectations regarding our financial position and funding
requirements; COMPASS’s expectations regarding its ongoing
preclinical work and clinical trials and development efforts, the
potential for COMPASS’s pivotal phase 3 program or other trials to
support regulatory filings and approvals; and our expectations
regarding the potential benefits of our COMP360 psilocybin
treatment. The forward-looking statements in this press release are
neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond COMPASS’s control and which could cause actual
results, levels of activity, performance or achievements to differ
materially from those expressed or implied by these forward-looking
statements.
These risks, uncertainties, and other factors include, among
others: market risks and other market conditions; clinical
development is lengthy and expensive process with uncertain
outcomes, and therefore our clinical trials may be delayed or
terminated and may be more costly than expected; we will require
substantial additional funding to achieve our business goals and if
we are unable to obtain this funding when needed and on acceptable
terms, we could be forced to delay, limit or terminate our product
development efforts; our efforts to obtain marketing approval from
the applicable regulatory authorities in any jurisdiction for
COMP360 or any of future product candidates may be unsuccessful;
establishing, maintaining, defending and enforcing our patents and
other intellectual property rights covering our investigational
COMP360 psilocybin therapy may be challenging and costly and our
efforts to protect our patents and other intellectual property
rights may be unsuccessful; our efforts to commercialize and to
obtain coverage and reimbursement for our investigational COMP360
psilocybin therapy, if approved, may be unsuccessful; and those
risks and uncertainties described under the heading “Risk Factors”
in COMPASS’s most recent annual report on Form 10-K or quarterly
report on Form 10-Q and in other reports we have filed with the
U.S. Securities and Exchange Commission (“SEC”), which are
available on the SEC’s website at www.sec.gov. HYPERLINK
"www.sec.gov" Except as required by law, COMPASS disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on COMPASS’s current
expectations and speak only as of the date hereof.
Enquiries
Media: Amy Lawrence, media@compasspathways.com, +44 7813 777
919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com,
+1 401 290 7324
COMPASS Pathways (NASDAQ:CMPS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
COMPASS Pathways (NASDAQ:CMPS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024